Curative Biotechnology, Inc. (CUBT)

Curative Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	0.22	0.02	0.06	0.06	0.67	0.16
Cash & Short-Term Investments	0.22	0.02	0.06	0.06	0.67	0.16
Cash Growth	34218.08%	-65.36%	-3.87%	-91.25%	317.33%	-
Other Receivables	-	-	0.12	-	0.03	-
Receivables	-	-	0.12	-	0.03	-
Prepaid Expenses	0.14	0.19	0.43	-	0.06	1.9
Other Current Assets	-	-	-	-	-	0.07
Total Current Assets	0.36	0.21	0.6	0.06	0.75	2.13
Property, Plant & Equipment	0	0	0.01	0.01	0.01	0
Other Intangible Assets	1.33	1.35	1.42	1.51	1.56	0.14
Long-Term Deferred Charges	0.6	0.6	0.57	0.49	0.09	-
Total Assets	2.29	2.16	2.6	2.06	2.41	2.27
Accounts Payable	4.17	4.08	3.49	3.43	0.73	0.1
Short-Term Debt	3.11	0.26	2.26	1.12	-	0.56
Current Portion of Long-Term Debt	-	2.73	-	-	-	-
Other Current Liabilities	-	-	-	0.04	0	0.01
Total Current Liabilities	7.28	7.08	5.75	4.6	0.73	0.66
Total Liabilities	7.28	7.08	5.75	4.6	0.73	0.66
Common Stock	0.1	0.09	0.09	0.06	0	0
Additional Paid-In Capital	37.78	36.88	34.99	29.81	10.56	3.58
Retained Earnings	-42.88	-41.89	-38.23	-32.41	-26.92	-8.1
Total Common Equity	-5	-4.92	-3.15	-2.54	-16.36	-4.52
Shareholders' Equity	-4.99	-4.91	-3.14	-2.54	1.68	1.61
Total Liabilities & Equity	2.29	2.16	2.6	2.06	2.41	2.27
Total Debt	3.11	2.99	2.26	1.12	-	0.56
Net Cash (Debt)	-2.89	-2.97	-2.2	-1.07	0.67	-0.4
Net Cash Per Share	-0.00	-0.00	-0.00	-0.00	0.00	-0.00
Filing Date Shares Outstanding	1,011	919.26	903.26	572.01	571.65	544.79
Total Common Shares Outstanding	1,011	919.26	903.26	572.01	570.65	333
Working Capital	-6.92	-6.86	-5.14	-4.54	0.02	1.47
Book Value Per Share	-0.00	-0.01	-0.00	-0.00	-0.03	-0.01
Tangible Book Value	-6.32	-6.26	-4.57	-4.05	-17.92	-4.66
Tangible Book Value Per Share	-0.01	-0.01	-0.01	-0.01	-0.03	-0.01

Updated Nov 30, 2022. Source: S&P Global Market Intelligence. Standard template. Financial Sources.